SEC 13F Intelligence

Propel Bio Management, LLC / FDMT

Propel Bio Management, LLC’s 4d Molecular Therapeutics In Position

Does Propel Bio Management, LLC own 4d Molecular Therapeutics In (FDMT)? Yes380.4K shares worth $4M (+2.26% of its 13F portfolio) as of Q1 2026.

Position Value
$4M
Q1 2026
Shares
380.4K
% of Portfolio
+2.26%
Quarters Held
1
currently held

Position History FDMT

Reported value by quarter
Q1 ’26: $4MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026380.4K$4M+2.26%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Propel Bio Management, LLC’s full portfolio or all institutional holders of FDMT.